Patents Assigned to Medimmune
  • Patent number: 10035843
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: July 31, 2018
    Assignee: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • Patent number: 10017580
    Abstract: Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: July 10, 2018
    Assignees: ADC Therpeutics S.A., Medimmune Limited
    Inventors: Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, David G. Williams
  • Patent number: 10016496
    Abstract: Respiratory Syncytial Virus is a common cold virus belonging to the family of paramyxovirus. RSV is virulent, easily transmissible and the most common cause of lower respiratory tract disease in children of less than 2 years of age. Up to 98% of children attending day care will be infected in a single RSV season. Between 0.5% and 3.2% of children with RSV infection require hospitalization. Approximately 90,000 hospital admissions and 4500 deaths per year were reported in United States. Major risk factors for hospitalization due to RSV are premature birth, chronic lung disease, congenital heart disease, compromised immunity, and age younger than 6 weeks in otherwise healthy children.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: July 10, 2018
    Assignee: MedImmune, LLC
    Inventor: Nancy Ulbrandt
  • Patent number: 10010624
    Abstract: Conjugates of specific PBD dimers with an antibody that binds to PSMA, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, or 10, optionally further comprising a VL domain having the sequence 5 according to any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: July 3, 2018
    Assignee: Medimmune Limited
    Inventors: Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
  • Patent number: 10011660
    Abstract: Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: July 3, 2018
    Assignee: MedImmune, LLC
    Inventors: Ping Tsui, Martin Borrok, II, William Dall'Acqua
  • Patent number: 10006026
    Abstract: Disclosed herein is a method for producing a recombinant polypeptide in a mammalian cell culture in which the mammalian cells have a modified microRNA activity level. In one embodiment, a microRNA activity level is increased. In another embodiment, a microRNA activity level is decreased. In a more particular embodiment, the mammalian cells have a reduced miRNA-let-7a activity level.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 26, 2018
    Assignee: MedImmune, LLC
    Inventors: Katie Streicher, Jonathan Jacobs, Robert W. Georgantas, III, Lydia Greenlees, Koustubh Ranade, Michael Bowen
  • Patent number: 9994636
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: June 12, 2018
    Assignees: MedImmune Limited, Cambridge Enterprise Limited
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • Patent number: 9981908
    Abstract: There are provided pyrrolysine analogs of the formulae (X), (I), (II), (V), (VI), (VII) and (VIII), in which the a, b, d, X, Y, Z, FG, R, R1, R2 and R3 are as defined in the claims, which are useful in bioconjugation processes and mutant proteins containing them.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: May 29, 2018
    Assignee: MedImmune Limited
    Inventors: Marcello Marelli, Michael van Brunt, Kenneth H. Grabstein
  • Patent number: 9968687
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 15, 2018
    Assignees: AbbVie Stemcentrx LLC, Medimmune Limited
    Inventors: Michael Torgov, Philip Wilson Howard
  • Publication number: 20180125973
    Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MED19447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
    Type: Application
    Filed: September 25, 2017
    Publication date: May 10, 2018
    Applicant: MedImmune Limited
    Inventors: Kris SACHSENMEIER, Erin SULT, Carl HAY, Edmund POON
  • Patent number: 9956299
    Abstract: Conjugates of specific PBD dimers with an antibody that binds to CD22, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: May 1, 2018
    Assignee: Medimmune Limited
    Inventors: Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
  • Patent number: 9957312
    Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: May 1, 2018
    Assignee: MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
  • Patent number: 9956298
    Abstract: A compound which is selected from A: and salts and solvates thereof.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: May 1, 2018
    Assignee: Medimmune Limited
    Inventors: Philip Wilson Howard, Arnaud Tiberghien, Thais Cailleau
  • Patent number: 9950078
    Abstract: Conjugates of specific PBD dimers with an antibody that that binds to CD19, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 2, 3, 4, 5 or 6, optionally further comprising a VL domain having the sequence according to any one of SEQ ID NOs. 7, 8, 9, 10, 11 or 12.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: April 24, 2018
    Assignee: Medimmune Limited
    Inventors: Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
  • Patent number: 9920124
    Abstract: The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Alan Hunter, Thomas Linke, Timothy Pabst, Michaela Wendeler, Xiangyang Wang, Christopher Thompson, Guoling Xi, Andrew Fulton
  • Patent number: 9913894
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: March 13, 2018
    Assignee: MedImmune, LLC
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Patent number: 9896505
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Patent number: 9884902
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 6, 2018
    Assignee: MedImmune Limited
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • Patent number: D821572
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: June 26, 2018
    Assignee: MedImmune, LLC
    Inventors: Corbin Zean Clawson, Roger Wongjung Liu, Janardhanan Anand Subramony
  • Patent number: D822199
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: July 3, 2018
    Assignee: MedImmune, LLC
    Inventors: Corbin Zean Clawson, Roger Wongjung Liu, Janardhanan Anand Subramony